Some of the highlights from the August issue include:
- The 10th International Brain Tumour Awareness Week is fast approaching and will be held from Saturday, 22nd October to Saturday, 29th October inclusive. No matter where you live, we'd be delighted if you would organise an activity and take part in this opportunity to increase awareness about brain tumours. For more information on how to get involved, and how to take part in the “World Walk”, please click here.
- Optune, the Tumor Treating Fields device developed by Novocure, is now recommended for newly diagnosed glioblastoma in the NCCN guidelines, For patients with good performance status, “Standard brain radiation therapy + concurrent temozolomide and adjuvant temozolomide + alternating electric field therapy” is included as a treatment option.
- Glioblastoma patients in the USA with private medical insurance have better survival and outcome, compared to those without insurance or with Medicaid health cover, according to a study published in the journal Cancer. Outcomes have been improving in glioblastoma patients with private medical insurance, but not in those without.
- Research published in the Journal of Clinical Oncology has found that that the intellectual decline experienced by many paediatric medulloblastoma patients varies according to tumour subtype: patients with SHH tumours experienced the least functional decline.
- It may be possible to predict the effectiveness of bevacizumab (Avastin) in individual glioblastoma patients with a blood neutrophil count test, according to research in Oncotarget. The study found that only those with a high neutrophil count benefited from bevacizumab.
- The International Low Grade Glioma registry is now inviting patients to enrol. Launched at the recent American Brain Tumor Association (ABTA) Annual Patient and Family Conference, the project aims to enrol 2,000 low grade glioma (LGG) patients to determine genetic variants associated with LGG, response to treatment, and clinical outcomes, as well as patient needs for information on their tumour and its treatment. The enrolment questionnaire is available here.
- You can read the IBTA e-News August edition in full online here. You can sign up to receive the e-News every month by registering here.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences.
To see an archive of existing e-News issues, click here.